Skip to content

Cotrimoxazole as an antibiotic-lock solution in preventing Catheter–Related Bacteremia in hemodialysis patients

evaluating of Cotrimoxazole as an antibiotic-lock solution in prophylaxis against Dialysis Catheter–Related Bacteremia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201305313043N8
Enrollment
90
Registered
2013-07-10
Start date
2013-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD patients in hemodialysis. Chronic kidney disease, stage 5

Interventions

Intervention 1: In experimental group: mix 2.5 ml ampule Cotrimoxazole ( 400/80) with 0.5 ml ampule heparin5000U then 1 ml distillated water added until total volume reach to 4 ml. In the end of dial
Treatment - Drugs
In experimental group: mix 2.5 ml ampule Cotrimoxazole ( 400/80) with 0.5 ml ampule heparin5000U then 1 ml distillated water added until total volume reach to 4 ml. In the end of dialysis section, ea
In Control group:1 ml of ampule heparin 5000 U with 3 ml distillated waterwill mix until total volume of 4 ml. In the end of dialysis section, each lumen of catheter were filled by this antibiotic so

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Recently diagnosed ESRD patients with temporary catheters. Exclusion criteria: active infection; Evidence of exit site of infection; Cirrhosis; encephalopathy; uncontrolled cancer; Any documented sensivity to sulfonamides family drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Catheter related infection occurence. Timepoint: during 6 month study, weekly assessment. Method of measurement: lab data from blood sample, clinical observation, follow up by questioniare.

Secondary

MeasureTime frame
Any cause of bacteremia infection. Timepoint: during 6 month study. Method of measurement: clinical observation.;Thrombosis in catheter. Timepoint: during 6 month study. Method of measurement: clinical observation.;Any cause of hospitalization and length of hospitalization. Timepoint: during 6 month study. Method of measurement: clinical observation.;Any cause of catheter removement. Timepoint: during 6 month study. Method of measurement: clinical observation.;Any cause of mortality during study. Timepoint: during 6 month study. Method of measurement: clinical observation.;Exit-site infection. Timepoint: during 6 month study. Method of measurement: clinical observation.;Occurring of antibiotic resistance ( colony induction or resistance infection to antibiotic in lock solution). Timepoint: during 6 month study. Method of measurement: lab data from blood sample.;Fungal infection. Timepoint: during 6 month study. Method of measurement: lab data from blood sample.;Adverse effects of antibiotic. Timepoint: during 6 month study. Method of measurement: clinical observation.;Risk of unusual bleeding from catheter during dialysis. Timepoint: during 6 month study. Method of measurement: clinical observation.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026